Evidence of activity seen in new data from ASA404 prostate cancer trial
Antisoma plc announced survival data from its phase II study of ASA404 in hormone-refractory prostate cancer, in which patients were randomised to receive either 1200 mg/m2 ASA404 plus the chemotherapy drug docetaxel or a control treatment of docetaxel alone.
The hazard ratio expressing the relative risk of death in the ASA404 and control groups favoured the ASA404 group (hazard ratio 0.8; 95% confidence intervals 0.46-1.39). Median survival in the two groups was similar at 17.0 and 17.2 months, respectively, while two-year survival was 33% with ASA404 and 23% in the control group.
Previously reported findings from the same trial have shown higher tumour response rates and markedly higher PSA response rates in patients receiving ASA404.
Antisoma's partner Novartis is considering what the next steps should be in prostate cancer as part of a wider analysis of potential indications for development. A phase III development programme is already ongoing in lung cancer, and plans for development in other indications are being considered.
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.